Subscribe to WHX Insights newsletter
Stay at the forefront of healthcare trends & innovations
Why your BCR-ABL results don't always add up
WHX Insights
May 21, 2026
1 Min Read
Shutterstock
You are monitoring a CML patient in sustained MMR. Suddenly, the BCR-ABL result comes back negative — or unexpectedly positive. Sound familiar?
Discordant molecular results are not just lab curiosities. They are clinical decision points that demand systematic investigation.
Three critical failure points
1. Pre-analytical pitfalls
RNA degradation remains the silent saboteur. Unrefrigerated transport beyond 48 hours can slash transcript detection by 50% — enough to mask a 0.5-log₁₀ increase.
PCR inhibitors (heme, immunoglobulins, anticoagulants) can block amplification entirely in low-burden disease.
Contamination causes false positives. One CMR patient can show an unexpected 0.04% IS positivity — traced to amplicon contamination in the pipetting area.
2. Analytical blind spots
Atypical transcripts (e6a2, e8a2, e19a2) affect ~2% of CML cases. Standard e13a2/e14a2 assays miss them completely.
Calibration drift creates inter-laboratory variations of several-fold — directly impacting response classification.
2025 ELN recommendation: Assays must detect all clinically relevant variants.
3. Interpretation gaps
Single discordant results require confirmation, not immediate therapy escalation.
Reports must flag technical limitations: "RNA degradation suspected" or "Rare transcript not targeted."
Your action protocol
✓ Process samples within 24 hours
✓ Validate control gene performance (assess Ct values)
✓ Confirm transcript coverage in atypical/relapsed cases
✓ Repeat unexpected results with fresh specimens
✓ Correlate molecular data with CBC and morphology
✓ Implement IS calibration and participate in EQA schemes
The bottom line
Discordant BCR-ABL results stem from biological variability, technical complexity, and pre-analytical vulnerabilities.
Resolving them transforms molecular diagnostics from analyser data into a dependable clinical decision tool.
Maintain vigilance across all testing phases. Communicate transparently. Interpret in context.
Your molecular report isn't just a number — it's a clinical compass.
Dive deeper into details. Read the latest WHX Insights Magazine now.
World Health Expo
Jan 25, 2027 TO Jan 28, 2027
|Dubai, UAE
Join us at World Health Expo (WHX) in Dubai — where the world of healthcare meets. WHX, formerly Arab Health, connects the healthcare industry's leading researchers, developers, innovators, and professionals all in one place. Whether you're on the hunt for a new product or service, want to learn from world-renowned speakers, or expand your professional network, WHX Dubai has everything you need to thrive in the Middle East's healthcare industry.
